Literature DB >> 21420282

The effects of cannabis use on neurocognition in schizophrenia: a meta-analysis.

Rachel A Rabin1, Konstantine K Zakzanis, Tony P George.   

Abstract

Patients with schizophrenia frequently report cannabis use, yet its effects on neurocognitive functioning in this population are still unclear. This meta-analysis was conducted to determine the magnitude of effect of cannabis consumption on cognition in schizophrenia without the confounding effects of other co-morbid substance use disorders. Eight studies met inclusion criteria yielding a total sample of 942. Three hundred and fifty six of these participants were cannabis users with schizophrenia, and 586 were patients with no cannabis use. Neuropsychological tests were grouped into seven domains (general cognitive ability and intelligence; selective, sustained and divided attention; executive abilities; working memory and learning; retrieval and recognition; receptive and expressive language abilities and visuo-spatial and construction abilities). Effect sizes were computed for each cognitive domain between cannabis-using patients and patients with no history of cannabis use. Effect size differences in cognitive performance in the schizophrenia group as a function of cannabis use were in the small to medium range, denoting superior performance in cannabis-using patients. Explanations for these findings are discussed and suggestions for future research in this area are recommended. Crown
Copyright © 2011. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21420282     DOI: 10.1016/j.schres.2011.02.017

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  38 in total

1.  Adverse Effects of Cannabis Use on Neurocognitive Functioning: A Systematic Review of Meta- Analytic Studies.

Authors:  Jacqueline C Duperrouzel; Karen Granja; Ileana Pacheco-Colón; Raul Gonzalez
Journal:  J Dual Diagn       Date:  2019-06-22

2.  Neurocognitive functioning of individuals with schizophrenia: using and not using drugs.

Authors:  Amber L Bahorik; Christina E Newhill; Shaun M Eack
Journal:  Schizophr Bull       Date:  2013-07-24       Impact factor: 9.306

3.  Heavy cannabis use prior psychosis in schizophrenia: clinical, cognitive and neurological evidences for a new endophenotype?

Authors:  Jasmina Mallet; Nicolas Ramoz; Yann Le Strat; Philip Gorwood; Caroline Dubertret
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-02-11       Impact factor: 5.270

4.  Associations between adolescent cannabis use and brain structure in psychosis.

Authors:  Hila Abush; Subroto Ghose; Erin A Van Enkevort; Brett A Clementz; Godfrey D Pearlson; John A Sweeney; Matcheri S Keshavan; Carol A Tamminga; Elena I Ivleva
Journal:  Psychiatry Res Neuroimaging       Date:  2018-03-28       Impact factor: 2.376

5.  AKT1 moderation of cannabis-induced cognitive alterations in psychotic disorder.

Authors:  Ruud van Winkel; Nico J M van Beveren; Claudia Simons
Journal:  Neuropsychopharmacology       Date:  2011-07-20       Impact factor: 7.853

6.  The adverse health effects and harms related to marijuana use: an overview review.

Authors:  K Ally Memedovich; Laura E Dowsett; Eldon Spackman; Tom Noseworthy; Fiona Clement
Journal:  CMAJ Open       Date:  2018-08-16

Review 7.  Cannabis regulatory science: risk-benefit considerations for mental disorders.

Authors:  Jacob T Borodovsky; Alan J Budney
Journal:  Int Rev Psychiatry       Date:  2018-05-29

8.  Effects of Extended Cannabis Abstinence on Cognitive Outcomes in Cannabis Dependent Patients with Schizophrenia vs Non-Psychiatric Controls.

Authors:  Rachel A Rabin; Mera S Barr; Michelle S Goodman; Yarissa Herman; Konstantine K Zakzanis; Stephen J Kish; Michael Kiang; Gary Remington; Tony P George
Journal:  Neuropsychopharmacology       Date:  2017-04-26       Impact factor: 7.853

9.  Cognitive and clinical outcomes associated with cannabis use in patients with bipolar I disorder.

Authors:  Raphael J Braga; Katherine E Burdick; Pamela Derosse; Anil K Malhotra
Journal:  Psychiatry Res       Date:  2012-07-18       Impact factor: 3.222

10.  Acute administration of Δ⁹ tetrahydrocannabinol does not prevent enhancement of sensory gating by clozapine in DBA/2 mice.

Authors:  Jason Smucny; Karen E Stevens; Jason R Tregellas
Journal:  Pharmacol Biochem Behav       Date:  2014-01-10       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.